Other mTOR inhibitors are deforolimus (an investigational agent in the management of sarcoma and breast cancer), zotarolimus (used as a coating in stents), ridaforolimus (used in eluting stents and in advanced malignancies) and temsirolimus (used in kidney cancer and under investigation for lymphoma, breast cancer, and other tumours). Here, MTOR is linked to lymphoma.